Recent News

• 04.22.2025 - iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio
• 04.22.2025 - iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio
• 04.21.2025 - AI-Powered Antibody Drug Discovery for Obesity and Cardiometabolic Diseases with Martin Brenner iBio
• 04.07.2025 - iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline
• 04.07.2025 - iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline
• 02.19.2025 - iBio to Begin Trading on the Nasdaq Stock Exchange
• 02.19.2025 - iBio to Begin Trading on the Nasdaq Stock Exchange

Recent Filings

• 04.22.2025 - 8-K Current report
• 04.22.2025 - EX-99.1 EX-99.1
• 04.08.2025 - EX-99.1 EX-99.1
• 04.08.2025 - 8-K Current report
• 04.07.2025 - 8-K Current report
• 04.07.2025 - EX-99.1 EX-99.1
• 03.03.2025 - CERT Certification by an exchange approving securities for listing
• 03.03.2025 - 25 Notification of the removal from listing and registration of matured, redeemed or retired securities
• 03.03.2025 - 8-A12B Registration of securities [Section 12(b)]
• 02.24.2025 - 4 Statement of changes in beneficial ownership of securities